These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37309076)

  • 21. Impact of a single non-sex-related stroke risk factor on atrial fibrillation and oral anticoagulant outcomes: a systematic review and meta-analysis.
    Grymonprez M; Steurbaut S; De Sutter A; Lahousse L
    Open Heart; 2020 Dec; 7(2):. PubMed ID: 33361315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation.
    Schaffer AL; Falster MO; Brieger D; Jorm LR; Wilson A; Hay M; Leeb K; Pearson S; Nasis A
    J Am Heart Assoc; 2019 Dec; 8(24):e014287. PubMed ID: 31795822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
    Potpara TS; Lip GY
    Prog Cardiovasc Dis; 2015; 58(2):177-94. PubMed ID: 26162958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thromboembolic, bleeding, and mortality risks among patients with nonvalvular atrial fibrillation treated with dual antiplatelet therapy versus oral anticoagulants: A population-based study.
    Lau WCY; Douglas IJ; Wong ICK; Smeeth L; Lip GYH; Leung WK; Siu CW; Cheung BMY; Mok MTC; Chan EW
    Heart Rhythm; 2020 Jan; 17(1):33-40. PubMed ID: 31377423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial.
    Pokorney SD; Cocoros N; Al-Khalidi HR; Haynes K; Li S; Al-Khatib SM; Corrigan-Curay J; Driscoll MR; Garcia C; Calvert SB; Harkins T; Jin R; Knecht D; Levenson M; Lin ND; Martin D; McCall D; McMahill-Walraven C; Nair V; Parlett L; Petrone A; Temple R; Zhang R; Zhou Y; Platt R; Granger CB
    JAMA Netw Open; 2022 May; 5(5):e2214321. PubMed ID: 35639381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database.
    Munir MB; Hlavacek P; Keshishian A; Guo JD; Mallampati R; Ferri M; Russ C; Emir B; Cato M; Yuce H; Hsu JC
    PLoS One; 2022; 17(2):e0263903. PubMed ID: 35176074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.
    van Walraven C; Hart RG; Singer DE; Laupacis A; Connolly S; Petersen P; Koudstaal PJ; Chang Y; Hellemons B
    JAMA; 2002 Nov; 288(19):2441-8. PubMed ID: 12435257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic implications of adherence to oral anticoagulants among patients with atrial fibrillation: Insights from MISOAC-AF trial.
    Patsiou V; Samaras A; Kartas A; Moysidis DV; Papazoglou AS; Bekiaridou A; Baroutidou A; Ziakas A; Tzikas A; Giannakoulas G
    J Cardiol; 2023 Apr; 81(4):390-396. PubMed ID: 36179772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.
    Dahal K; Kunwar S; Rijal J; Schulman P; Lee J
    Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation.
    Freeman JV; Shrader P; Pieper KS; Allen LA; Chan PS; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel JA; Singer DE; Go AS; Hylek EM; Steinberg BA; Peterson ED; Piccini JP
    Circ Arrhythm Electrophysiol; 2019 Dec; 12(12):e007612. PubMed ID: 31830822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral anticoagulant discontinuation in patients with nonvalvular atrial fibrillation.
    Kachroo S; Hamilton M; Liu X; Pan X; Brixner D; Marrouche N; Biskupiak J
    Am J Manag Care; 2016 Jan; 22(1):e1-8. PubMed ID: 26799200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry.
    Essien UR; Chiswell K; Kaltenbach LA; Wang TY; Fonarow GC; Thomas KL; Turakhia MP; Benjamin EJ; Rodriguez F; Fang MC; Magnani JW; Yancy CW; Piccini JP
    JAMA Cardiol; 2022 Dec; 7(12):1207-1217. PubMed ID: 36287545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study.
    Yang WY; Du X; Jiang C; He L; Fawzy AM; Wang L; Liu C; Xia SJ; Chang SS; Guo XY; Li SN; Tang RB; Liu N; Bai R; Sang CH; Jiang CX; Yu RH; Long DY; Dong JZ; Lip GYH; Ma CS
    Europace; 2020 Jan; 22(1):90-99. PubMed ID: 31909431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
    O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
    Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
    Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term risk of stroke and bleeding post-atrial fibrillation ablation.
    Joza J; Samuel M; Jackevicius CA; Behlouli H; Jia J; Koh M; Tsadok MA; Tang ASL; Verma A; Pilote L; Essebag V
    J Cardiovasc Electrophysiol; 2018 Oct; 29(10):1355-1362. PubMed ID: 30047574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation.
    Chan YH; Chuang C; Chan CC; Lee HF; Huang YC; Huang YT; Chang SH; Wang CL; Chao TF; Kuo CT; Yeh YH; Chen SA
    Cardiovasc Diabetol; 2020 Mar; 19(1):30. PubMed ID: 32156277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis.
    Kim IS; Kim HJ; Kim TH; Uhm JS; Joung B; Lee MH; Pak HN
    J Cardiol; 2018 Oct; 72(4):284-291. PubMed ID: 29706404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.